"Funding from Eurostars, in fierce competition with many other projects, confirms the strength of Intervacc, our technology and our business strategy to develop new vaccines in animal health. We see this as an extremely important step forward for the company", says Jan-Ingmar Flock, CEO of Intervacc.

Innovative vaccine development with great potential

Intervacc has been cooperating with Moredun Scientific in Edinburgh for some time with the aim of developing a vaccine, with the project name INV274, against infection of piglets caused by Streptococcus suis. The project phase that Intervacc, together with Moredun Scientific, now has been granted funding for, includes funds for implementing a number of important development steps within the INV274 project (including pre-clinical efficacy studies in piglets, antibody analysis and vaccination also of pregnant sows). The European Commission has concluded that the technical and scientific cooperation between Intervacc and Moredun Scientific has a clear European added value. In addition, the final results of the innovative collaborative project are expected to create significant market change at commercialization.

Streptococcus suis causes severe infections in some pig herds with devastating results for the pig industry and has also given rise to infection in humans. There are almost one billion pigs worldwide and the need for a working vaccine is in great demand. Existing conventional vaccines have limited effect and do not protect against all strains. The current project uses the same successful technology with recombinant proteins from the bacterial surface as used in Strangvac, Intervacc's vaccine against equine strangles.

Vaccine development is a crucial tool for reducing overconsumption of antibiotics and for reducing the widespread resistance of antibiotics. Globally, more antibiotics are used in agriculture than in human medicine, in some countries up to 80% as a preventive and growth-promoting measure. The use and development of vaccines in animal health has annual growth of about 9%. Intervacc has recently also been awarded funds from Vinnova for the development of a vaccine against Staphylococcus aureus that causes mastitis infections.

CEO Jan-Ingmar Flock, summarizes "The quality requirements and the fact that several of our projects have been rated so well by independent expert reviewers in a short while, confirms that Intervacc's project portfolio for a new generation of animal health vaccines is of great interest".

For more information please contact:
Jan-Ingmar Flock, CEO
E-mail: jan-ingmar.flock@intervacc.com
Phone: +46-8-120 10 602 or +46-73-334 14 11

This information is information that Intervacc AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on July 12, 2018.

About Eurostars-2 programme

Eurostars supports international innovative projects led by research and development- performing small- and medium-sized enterprises (R&D-performing SMEs). With its bottom-up approach, Eurostars supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world.

Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 36 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020. In the 2014-2020 period it has a total public budget of €1.14 billion. Read more about Eurostars at https://www.eurostars-eureka.eu/

About Moredun Scientific

Moredun Scientific is a contract research organisation specialising in animal health and biosafety testing of biopharmaceuticals enabling companies to develop, register and commercialize their products. Their expert staff work with a global client base to ensure on time delivery of studies to the required quality standards. Read more at https://www.moredun.org.uk/commercial

About Intervacc

Intervacc AB (publ) is a company within the Biotechnology sector. The Company's main area is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company's vaccine candidates are based on several years of research at Karolinska Institute and Swedish University of Agricultural Research where the foundation was laid for the company's research and development work. The Intervacc share has been listed on the NASDAQ First North market since April 2017 with Eminova Fondkommission AB as Certified Adviser.